鴉片類藥物使用障礙全球市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球鴉片類藥物使用障礙市場預計將從2025年的66.2億美元成長至2034年的152.8億美元，2026年至2034年的複合年成長率（CAGR）為9.74%。隨著有效的治療策略和減少危害措施成為醫療保健系統的優先事項，鴉片類藥物使用障礙市場正在經歷重大變化。鴉片類藥物成癮和過量用藥事件的日益普遍推動了對先進治療性介入的需求，包括Buprenornhine、美沙酮和新型非鴉片類藥物療法。結合輔助性治療（MAT）、行為療法和數位化藥物依從性監測的綜合護理模式對於長期康復至關重要。監管措施和公共衛生宣傳活動正在進一步促進患者獲得創新療法。

技術和臨床的進步正在提升治療的有效性和可近性。數位健康平台提供遠端監測、風險預測預警和用藥依從性追蹤等功能，從而實現個人化治療策略。新型藥物製劑，例如緩釋製劑和舌下給藥系統，在提高患者依從性的同時，也降低了藥物濫用的可能性。對非依賴性鎮痛藥、疫苗干預和神經調控療法的研究正在開闢新的治療途徑。醫療專業人員正擴大利用遠端醫療和行動醫療技術來服務醫療資源匱乏的人群，並提高干預措施的成功率。

未來前景將由綜合公共衛生策略、政策支援和製藥產業的創新共同塑造。北美地區由於其高盛行率和成熟的治療基礎設施，仍然是最大的市場，而新興經濟體正在逐步擴大循證治療的覆蓋範圍。醫療服務提供者、數位健康創新者和製藥公司之間的策略夥伴關係正在建立一個涵蓋診斷、治療和復健支援的綜合生態系統。隨著公眾意識的提高、技術的進步和治療方案的拓展，鴉片類藥物使用障礙市場有望提供更有效、以患者為中心的解決方案，以應對醫療和社會方面的挑戰。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球鴉片類藥物使用障礙市場：依藥物分類

• 市場分析、洞察與預測
• 納曲酮
• Buprenornhine
• 梅塔頓
• 其他

第5章 全球鴉片類藥物使用障礙市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射給藥
• 其他

第6章：全球鴉片類藥物使用障礙市場：依分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 其他

第7章 全球鴉片類藥物使用障礙市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Indivior PLC
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Collegium PharmaceuticalInc
  • Alkermes Inc
  • Orexo AB
  • Titan PharmaceuticalsInc
  • Omeros Corporation
  • Camurus AB
  • Hikma Pharmaceuticals PLC
  • Mallinckrodt Pharmaceuticals
  • Viatris Inc.（Mylan NV）
  • Boehringer Ingelheim International GmbH
  • Janssen PharmaceuticalsInc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Endo International Plc
  • Purdue Pharma LP
  • Assertio HoldingsInc

The global opioids use disorder market size is expected to reach USD 15.28 Billion in 2034 from USD 6.62 Billion in 2025, growing at a CAGR of 9.74 during 2026-2034.The opioids use disorder market is undergoing significant evolution as healthcare systems prioritize effective treatment strategies and harm reduction measures. Rising prevalence of opioid dependence and overdose incidents has intensified demand for advanced therapeutic interventions, including buprenorphine, methadone, and emerging non-opioid pharmacotherapies. Integrated care models combining medication-assisted treatment (MAT), behavioral therapy, and digital adherence monitoring are becoming essential for long-term recovery outcomes. Regulatory initiatives and public health campaigns are further supporting patient access to innovative therapies.

Technological and clinical advancements are expanding treatment efficacy and accessibility. Digital health platforms provide remote monitoring, predictive risk alerts, and adherence tracking, enabling personalized treatment strategies. Novel drug formulations, including extended-release and sublingual delivery systems, are improving patient compliance while reducing misuse potential. Research into non-addictive analgesics, vaccine-based interventions, and neuromodulation therapies is creating new therapeutic avenues. Healthcare providers are increasingly leveraging telemedicine and mobile health technologies to reach underserved populations and improve intervention success rates.

The future trajectory is defined by integrated public health strategies, policy support, and pharmaceutical innovation. North America remains the largest market due to high prevalence and mature treatment infrastructure, while emerging economies are gradually scaling access to evidence-based therapies. Strategic partnerships between healthcare providers, digital health innovators, and pharmaceutical companies are fostering a comprehensive ecosystem for diagnosis, treatment, and recovery support. As awareness, technology, and therapeutic options expand, the opioids use disorder market is poised to provide more effective, patient-centric solutions that address both medical and societal challenges.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug

• Naltrexone
• Buprenorphine
• Methadone
• Others

By Route of Administration

• Oral Administration
• Injectable Administration
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Indivior PLC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Collegium Pharmaceutical, Inc., Alkermes Inc., Orexo AB, Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus AB, Hikma Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals, Viatris Inc. (Mylan N.V.), Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Endo International plc, Purdue Pharma L.P., Assertio Holdings, Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OPIOIDS USE DISORDER MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Naltrexone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Buprenorphine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Methadone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OPIOIDS USE DISORDER MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OPIOIDS USE DISORDER MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OPIOIDS USE DISORDER MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OPIOIDS USE DISORDER INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Indivior PLC
  • 9.2.2 Teva Pharmaceutical Industries Ltd
  • 9.2.3 Pfizer Inc
  • 9.2.4 Collegium PharmaceuticalInc
  • 9.2.5 Alkermes Inc
  • 9.2.6 Orexo AB
  • 9.2.7 Titan PharmaceuticalsInc
  • 9.2.8 Omeros Corporation
  • 9.2.9 Camurus AB
  • 9.2.10 Hikma Pharmaceuticals PLC
  • 9.2.11 Mallinckrodt Pharmaceuticals
  • 9.2.12 Viatris Inc. (Mylan N.V.)
  • 9.2.13 Boehringer Ingelheim International GmbH
  • 9.2.14 Janssen PharmaceuticalsInc
  • 9.2.15 Sanofi S.A
  • 9.2.16 Sun Pharmaceutical Industries Ltd
  • 9.2.17 Endo International Plc
  • 9.2.18 Purdue Pharma L.P
  • 9.2.19 Assertio HoldingsInc